@vanjohn10.bsky.socialZacks' Senior Life Sciences Analyst John Vandermosten initiates on AEON Biopharma with a $2.00 price target.
$AEON: Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar:
s27.q4cdn.com/906368049/fi...
#BiotechStocks #Biosimilars #Biologics #BotulinumToxin #ABP450 #MarketNews
@medicinesuk.bsky.socialIn the latest episode of the Medicines Matters podcast, we discuss the UK biosimilar void and what it will mean for future UK supply.
To listen to the full episode click below.
@zackssmallcap.bsky.social$AEON is developing ABP-450 as a Botox biosimilar. No biosimilar to Botox has been approved since it launched in 1989. PD and bridging studies are expected in 2027: youtu.be/mPZGVIiJw6I
@newsen.bsky.socialKexing Biopharm Stands Out at CPHI Milan 2026: New Horizons for Global Cooperation #None #Milan #Biosimilars #Kexing_Biopharm #CPHI_Milan
@newsen.bsky.socialExploring Kexing Biopharm's Global Impact at CPHI Milan 2026 #None #Milan #Biosimilars #Kexing_Biopharm #CPHI_Milan
@pharmalogsummit.bsky.socialThe 9th edition of the Global Pharma Logistics Summit (GPLS) takes place on 9 October 2026, bringing industry leaders together to explore the future of pharmaceutical logistics and supply chains.
#GPLS2026 #GlobalPharmaLogisticsSummit #PharmaLogistics #Biopharma #Biosimilars #ColdChain
@newsen.bsky.socialThyme Therapeutics: Revolutionizing Cancer Drug Affordability with Biosimilars #USA #Nashville #oncology #Biosimilars #Thyme_Companies
@newsen.bsky.socialFresenius Finalizes Acquisition of mAbxience to Enhance Biosimilars Portfolio Expansion #Madrid #Germany #Biosimilars #mAbxience #Fresenius
@nikolospharma.bsky.social
@pharmazeitung.bsky.socialSeit April gilt für #Biosimilars ein verpflichtender Austausch ähnlich den #Generika. Im Gegensatz zu Letztgenannten sind exklusive Rabattverträge bei biologischen Arzneimitteln aber noch verboten. Bei einer Diskussionsrunde in der Pharma-World wurde deutlich, dass das am besten so bleiben sollte.
@4040rec.bsky.social
@pharmaphorum.bsky.social#Sandoz has told #investors that it intends to double its #netsales between 2025 and 2035, and sees a pivot towards #biosimilars as the driving force for that growth.